NICE Single Technology Appraisal Guidance No 237 – Ranibizumab
for the treatment of diabetic macular oedema
This NICE guidance was published on 30 November 2011. The web
reference for the appraisal and other related documents is:
NHSScotland should note
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (711/11) on
this medication for this indication in July 2011. This stated
Ranibizumab (Lucentis®) is not
recommended for use within NHS Scotland for the treatment of visual
impairment due to diabetic macular oedema in adults.
Access the advice of SMC
3. There is no material difference between the recommendations
of the NICE STA and SMC.
If you need further assistance, please contact Eleanor Brownlee
Published Date: 30 November 2011